Solifenacin: Treatment of overactive bladder

Drugs of Today

Volumn 40, Issue 4, 2004, Pages 343-353

  Chilman Blair, Kim ^a   Bosch, J L H Ruud ^b  

^a PROUS SCIENCE   (Spain)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; KETOCONAZOLE; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE;

ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; BLADDER CONTRACTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DETRUSOR MUSCLE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; META ANALYSIS; MICTURITION; OVERACTIVE BLADDER; PERSONALITY DISORDER; PHLEBITIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS, PHASE III; DRUG EVALUATION, PRECLINICAL; HUMANS; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; RECEPTOR, MUSCARINIC M3; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC;

EID: 2642523146     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.4.820080     Document Type: Review

References (37)

1. Abrams, P. The standardisation of terminology of urinary tract function. Neurourol Urodyn 2002, 21: 167-78.
2. Milsom, I., Abrams, P., Cardozo, L., Roberts, R., Thuroff, J., Wein, A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001, 87: 760-6.
3. Richelson, E., Elliot, D. Advances in medical management of overactive bladder. Mayo Clin Proc 2003, 78: 681-3.
4. Wagner, T., Hu, T. Economic costs of urinary incontinence in 1995. Urology 1998, 51: 355-61.
5. Andersson, K., Hedlund, P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002, 60 (5 Suppl. 1): 13-20.
6. Wallis, R. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists. Life Sci 1995, 56: 861-8.
7. Ikeda, K., Kobayashi, S., Suzuki, M. et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmied Arch Pharmacol 2002, 366: 97-103.
8. Andersson, K., Yoshida, M. Antimuscarinics and the overactive detrusor - Which is the main mechanism of action? Eur Urol 2003, 43: 1-5.
9. Herbison, P., Hay-Smith, J., Ellis, G., Moore, K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review. BMJ 2003, 326: 841-4.
10. Chess-Williams, R., Chapple, C., Yamanishi, T., Yasuda, K., Sellers, D. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001, 21: 243-8.
11. Caulfield, M., Birdsall, N. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998, 50: 279-89.
12. Matsui, M., Motomura, D., Karasawa, H. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci 2000, 97: 9577-84.
13. Chapple, C., Yamanishi, T., Chess-Williams, R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002, 60 (5 Suppl. 1): 82-8.
14. Gillberg, P., Sundquist, S., Nilvebrant, L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998, 349: 285-92.
15. Newgreen, D., Anderson, C., Carter, A. Darifenacin: A novel bladder-selective agent for the treatment of urinary urge incontinence. Neurourol Urodyn 1995. 14: 555-7.
16. Yamada, S., Oki, T., Kimura, R., Sato, S., Miyata, K. Muscarinic receptor binding characteristics of a novel anticholinergic agent, YM905, in the urinary bladder and other tissues of mice. Neurourol Urodyn 2001, 20: Abstr. 58.
17. Oki, T., Yamada, T., Kusaka, T. et al. Ex vivo binding characteristics of a novel anticholinergic agent, YM905, to muscarinic receptors in mouse tissues. Jp J Pharmacol 2001, 85 (Suppl. 1): Abstr. P625.
18. Kuipers, M., Tran, D., Krauwinkel, W., Abila, B., Mulder, H. Absolute bioavailability of YM905 in healthy male volunteers: A single-dose, randomized, two-period crossover study. 32nd Annu Meet Int Continence Soc 2002, Abstr. 436.
19. Smulders, R., Tan, H., Krauwinkel, W., Abila, B., van Zijtveld, J. A placebo-controlled, doserising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of YM905. 32nd Annu Meet Int Continence Soc 2002, Abstr. 437.
20. Smulders, R.A., Krauwinkel, W., van Zijtveld, J. Pharmacokinetics, pharmacodynamics, and safety of YM905 in healthy, elderly subjects. J Am Geriatr Soc 2003, 51 (4 Suppl. 1): Abstr. P172.
21. Smulders, R., Krauwinkel, W., Abila, B., van Zijtveld, J. 10- and 20-mg oral doses of YM905, a novel, bladder-selective antimuscarinic: Pharmacokinetics, pharmacodynamics, and safety in healthy, elderly men and women. 32nd Annu Meet Int Continence Soc 2002, Abstr. 435.
22. Taisuke, U., Smulders, R., Abila, B., Mulder, H. Pharmacokinetics of YM905, a novel, bladder-selective antimuscarinic, are not adversely affected by food. 32nd Annu Meet Int Continence Soc 2002, Abstr. 448.
23. Smith, N., van Zijtveld, J., Swart, P.J. Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM905. 32nd Annu Meet Int Continence Soc 2002, Abstr. 446.
24. Ukai, M., Hatanaka, T., Ohtake, A., Sato, S., Miyata, K. Tissue-selective profile of YM905 for urinary bladder over salivary gland in rats. Eur Urol Suppl 2003, 2: Abstr. 557.
25. Sellers, D., Hill, C., White, S., Korstanje, C., Chess-Williams, R., Chapple, C. Selectivity of solifenacin in the rat bladder versus salivary gland. Eur Urol Suppl 2003, 2: Abstr. 672.
26. Sellers, D., Hill, C., White, S., Korstanje, C., Chess-Williams, R., Chapple, C. Investigation of the selectivity of solifenacin in rat bladder vs salivary gland. J Urol 2003, 169 (4, Suppl.): Abstr. 152.
27. Hatanaka, T., Ukai, M., Ohtake, A. et al. In vitro tissue selective profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys. 32nd Annu Meet Int Continence Soc 2002, Abstr. 312.
28. Smulders, R., van Alphen, W., Visser, J., Abila, B., van Zijtveld, J. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: Safety, tolerability, and pharmacokinetics. 32nd Annu Meet Int Continence Soc 2002, Abstr. 438.
29. Smith, N., Grimes, I., Ridge, S., Tempel, D., Uchida, T. YM905 is effective and safe as treatment of overactive bladder in women and men: Results from phase II study. 32nd Annu Meet Int Continence Soc 2002, Abstr. 222.
30. Chapple, C., Arano, P., Bosch, J., De Ridder, D., Kramer, A., Ridder, A. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study. 32nd Annu Meet Int Continence Soc 2002, Abstr. 75.
31. Kaufman, J., Knapp, P., Siami, P. et al. YM905 10 mg increases the proportion of male and female patients with overactive bladder who become continent. J Am Geriatr Soc 2003, 51 (4 Suppl. 1): Abstr. P168.
32. Gittleman, M., Chu, F., Klimberg, I. et al. Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder. J Urol 2003, 169 (4 Suppl.): Abstr. DP43.
33. Kaufman, J., Knapp, P., Siami, P. et al. YM905 10 mg increases the proportion of male and female patients with overactive bladder who become continent. J Urol 2003, 169 (4 Suppl.): Abstr. DP49.
34. Cardozo, L., Kuzmin, I., Lisec, M.L. et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder. J Am Geriatr Soc 2003, 51 (4 Suppl. 1): Abstr. P74.
35. Cardozo, L., Kuzmin, I., Lisec, M.L. et al. YM905 in symptomatic overactive bladder: Results of a phase 3A randomised, placebo-controlled trial. J Urol 2003, 169 (4 Suppl. 1): Abstr. DP47.
36. Cardozo, L., Kuzmin, I., Lisec, M. et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder. Eur Urol Suppl 2003, 2: Abst. 104.
37. Chapple, C.R., Rechberger, T., AI-Shukri, S. et al. A double-blind, randomised, placebo and tolterodine controlled trial with YM905 in symptomatic overactive bladder. J Am Geriatr Soc 2003, 51 (4 Suppl. 1): Abstr. P76.